Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Fulcrum Therapeutics (FULC – Research Report) yesterday and set a price target of $4.50. The company’s shares closed yesterday at $5.43.
According to TipRanks, Ahmad is a 4-star analyst with an average return of 5.1% and a 47.42% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, PTC Therapeutics, and Argenx Se.
Fulcrum Therapeutics has an analyst consensus of Hold, with a price target consensus of $9.13.
See today’s best-performing stocks on TipRanks >>
FULC market cap is currently $335.7M and has a P/E ratio of -2.99.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Read More on FULC:
- Fulcrum Therapeutics (NASDAQ:FULC) Skyrockets After FDA Lifts Clinical Hold on Sickle Cell Disease Candidate
- FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics names Alan Musso as CFO
- Fulcrum Therapeutics expects cash to fund operations into mid-2025
